A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner

Immune checkpoint therapy has shown great promise in the treatment of cancers with a high mutational burden, such as mismatch repair-deficient colorectal carcinoma (dMMR CRC). However, many patients fail to respond to immune checkpoint therapy. Using a mouse model of dMMR CRC, we demonstrated that t...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Sayes, Nader, Vito, Alyssa, Salem, Omar, Workenhe, Samuel Tekeste, Wan, Yonghong, Mossman, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915181/
https://www.ncbi.nlm.nih.gov/pubmed/35163675
http://dx.doi.org/10.3390/ijms23031754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915181/
https://www.ncbi.nlm.nih.gov/pubmed/35163675
http://dx.doi.org/10.3390/ijms23031754

Ejemplares similares